

## EQA round: AP2/24 - Antithrombotic Agents

Deadline: 13.9.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>Set 1</b>															
(108) <b>Apixaban</b>	[µg/L]				46							46	46	100	
<b>Sample A1</b>		446	25	5,7	46		CVP	446	9,3	25%	334	558	46	46	100
(38) Werfen (IL)		458	9	2	13	0							13		
(94) Stago		451	13	2,8	7	0							7		
(149) Siemens (Dade, BN, Dimension)		430	55	13	17	0							17		
(179) Siemens		410	89	22	6	1							6		
Other					3	0							3		
							3x 193								
<b>Sample B1</b>		222	12	5,4	46		CVP	222	4,3	25%	166	278	46	46	100
(38) Werfen (IL)		223	6,2	2,8	13	0							13		
(94) Stago		217	9,6	4,5	7	0							7		
(149) Siemens (Dade, BN, Dimension)		227	13	5,5	17	0							17		
(179) Siemens		218	14	6,5	6	0							6		
Other					3	0							3		
							3x 193								
<b>Set 2</b>															
(109) <b>Dabigatran</b>	[µg/L]				38							38	37	97	
<b>Sample A2</b>		231	21	9,2	38		CVP	231	8,4	30%	161	301	38	37	97
(38) Werfen (IL)		227	31	13	12	0							12		
(149) Siemens (Dade, BN, Dimension)		225	16	7,1	11	0							11		
(179) Siemens		225	8,2	3,6	6	0							6		
(193) HYPHEN BioMed		249	19	7,5	9	0							9		
<b>Sample B2</b>		95	10	11	38		CVP	95	4,1	30%	66,5	124	38	38	100
(38) Werfen (IL)		95,8	8,4	8,7	12	0							12		
(149) Siemens (Dade, BN, Dimension)		88,1	6,7	7,6	11	0							11		
(179) Siemens		89	1,5	1,7	6	0							6		
(193) HYPHEN BioMed		109	13	12	9	0							9		
<b>Set 3</b>															
(110) <b>Rivaroxaban</b>	[µg/L]				51							51	50	98	
<b>Sample A3</b>		288	16	5,7	51		CVP	288	5,6	25%	216	360	51	51	100
(38) Werfen (IL)		279	11	4	14	0							14		
(94) Stago		287	24	8,3	7	0							7		
(149) Siemens (Dade, BN, Dimension)		290	14	4,8	18	0							18		
(179) Siemens		303	42	14	7	0							7		
Other					5	0							5		
							1x 162, 4x 193								
<b>Sample B3</b>		90,5	5,8	6,4	51		CVP	90,5	2	25%	67,8	114	51	50	98
(38) Werfen (IL)		92,5	5,7	6,1	14	0							14		
(94) Stago		80,5	5,2	6,4	7	0							7		
(149) Siemens (Dade, BN, Dimension)		90,9	5,3	5,9	18	0							18		
(179) Siemens		93	4,4	4,8	7	0							7		
Other					5	0							5		
							1x 162, 4x 193								